Diabetes

Ilya Pharma has received approval from the Swedish Medical Product Agency and Swedish Ethical Review Authority to initiate a Phase II clinical study of its ILP100 gene therapy for the treatment of difficult diabetic wounds (EudraCT 2021-000563-69). ILP100h has recently been assigned the INN name emilimogene sigulactibac by the World Health Organization and represents a […]

Scohia has presented the results of a Phase I clinical trial for SCO-267, an orally bioavailable GPR40 full agonist, at the Virtual Scientific Sessions of the American Diabetes Association. Free fatty acid receptor 1 (GPR40) is a G protein-coupled receptor expressed in pancreatic islet and enteroendocrine cells, and SCO-267 is potentially a first in class […]

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide has the potential to achieve […]

According to GlobalData, the diabetes market has gone through significant maturation, attributed to increased innovation and modernisation of therapeutic treatments over the past 20 years. The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to continue increasing in the foreseeable future. As a […]

Research published in Nature Communications by a team from Lund University in Sweden has discovered that in Type 2 diabetes, a specific gene influences muscle stem cells’ ability to create new mature muscle cells. “In people with Type 2 diabetes, the VPS39 gene is significantly less active in the muscle cells than it is in […]

Lu Rahman looks at the role precision medicine is playing in how we approach the patient and the way we  treat disease. We hear increasingly about the shift away from one size fits all medicine. It does of course, make perfect sense and in the cancer space in particular we have been well versed on […]

According to new research, two new but commonly-used diabetes drugs, one of which is also now approved for use in heart failure in people with or without diabetes, might be more effective in people with an Asian background than in people with a White background.    The study, led by the University of Glasgow, found […]

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai. Its clinical trial showed that this medication can improve the heart’s size, shape, and function, leading to better exercise capacity and quality of life, […]